422 related articles for article (PubMed ID: 19319690)
41. An in vitro and in silico study on the flavonoid-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) through Caco-2 monolayers.
Schutte ME; Freidig AP; van de Sandt JJ; Alink GM; Rietjens IM; Groten JP
Toxicol Appl Pharmacol; 2006 Dec; 217(2):204-15. PubMed ID: 16997339
[TBL] [Abstract][Full Text] [Related]
42. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
43. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
44. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
45. Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers.
Lee K; Ng C; Brouwer KL; Thakker DR
J Pharmacol Exp Ther; 2002 Nov; 303(2):574-80. PubMed ID: 12388638
[TBL] [Abstract][Full Text] [Related]
46. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
47. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
48. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
Honda Y; Ushigome F; Koyabu N; Morimoto S; Shoyama Y; Uchiumi T; Kuwano M; Ohtani H; Sawada Y
Br J Pharmacol; 2004 Dec; 143(7):856-64. PubMed ID: 15504753
[TBL] [Abstract][Full Text] [Related]
49. Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
Takusagawa S; Ushigome F; Nemoto H; Takahashi Y; Li Q; Kerbusch V; Miyashita A; Iwatsubo T; Usui T
Mol Pharm; 2013 May; 10(5):1783-94. PubMed ID: 23560393
[TBL] [Abstract][Full Text] [Related]
50. Nucleobase- and p-glycoprotein-mediated transport of AG337 in a Caco-2 cell culture model.
Hu M; Chen J
Mol Pharm; 2004; 1(3):194-200. PubMed ID: 15981922
[TBL] [Abstract][Full Text] [Related]
51. Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.
Li H; Jin HE; Kim W; Han YH; Kim DD; Chung SJ; Shim CK
Pharm Res; 2008 Nov; 25(11):2601-12. PubMed ID: 18654741
[TBL] [Abstract][Full Text] [Related]
52. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
53. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
54. Rosmarinic acid, the active component of
Li M; Yin D; Li J; Shao F; Zhang Q; Jiang Q; Zhang M; Yang Y
Pharmazie; 2020 Jan; 75(1):18-22. PubMed ID: 32033628
[No Abstract] [Full Text] [Related]
55. Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.
Vadlapatla RK; Vadlapudi AD; Kwatra D; Pal D; Mitra AK
Int J Pharm; 2011 Nov; 420(1):26-33. PubMed ID: 21864659
[TBL] [Abstract][Full Text] [Related]
56. Breast cancer resistance protein BCRP (ABCG2)-mediated transepithelial nitrofurantoin secretion and its regulation in human intestinal epithelial (Caco-2) layers.
Wright JA; Haslam IS; Coleman T; Simmons NL
Eur J Pharmacol; 2011 Dec; 672(1-3):70-6. PubMed ID: 22004608
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
Miller DW; Hinton M; Chen F
Neurourol Urodyn; 2011 Nov; 30(8):1633-8. PubMed ID: 21826715
[TBL] [Abstract][Full Text] [Related]
58. Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.
Schrickx JA; Fink-Gremmels J
Br J Pharmacol; 2007 Feb; 150(4):463-9. PubMed ID: 17211460
[TBL] [Abstract][Full Text] [Related]
59. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
[TBL] [Abstract][Full Text] [Related]
60. Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
Lumen AA; Li L; Li J; Ahmed Z; Meng Z; Owen A; Ellens H; Hidalgo IJ; Bentz J
PLoS One; 2013; 8(8):e69394. PubMed ID: 23976943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
